Trial Information

Summary: Cognitive Function in Cancer Chemotherapy (CFCC)

To determine the frequency and nature of cognitive deficits in patients receiving treatment for breast or colorectal cancer.

To collect samples for future evaluation of genes which may impact on the frequency or severity of cognitive deficits.

Patient Inclusion Criteria:

• We will include all newly diagnosed breast and colorectal cancer patients who are expected to receive chemotherapy and/or hormone therapy and have not received prior chemotherapy treatment for cancer.
• Prior surgical and/or radiation treatment (excluding radiation to the brain) will not be exclusionary.
• We will include all stages of disease for both groups of patients.
• Metastatic patients will be included as long as metastases do not involve the brain.
• Both males and females will be eligible to participate.
• Individuals age 18 and older will be eligible to participate.
• All patients regardless of life expectancy will be eligible to participate.
• We will not exclude subjects based on use of psychotropic medications, such as benzodiazepines, but will record the use of such medications and treat it as a covariate in the analysis.

Patient Exclusion Criteria:
See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:42:53 AM